Posted inBiotechnology
Cutting-Edge Molecular Dynamics Simulations Achieve Remarkable Precision in RNA Folding Studies
Ribonucleic acid, more commonly known as RNA, has emerged as a molecular superstar in the world of biology, far surpassing…
Posted inBiotechnology
Health Quality of Life in Families with Severe BPD
In a groundbreaking exploration of pediatric healthcare and family dynamics, a recent study published in the Journal of Perinatology brings…
Posted inBiotechnology
Plasma Lipidomics Reveals Biomarkers in Bladder Cancer
Non-muscle invasive bladder cancer (NMIBC) remains a formidable challenge in oncology, largely due to the limitations of current diagnostic tools.…
Posted inBiotechnology
Publisher’s note: Questex acquisition supercharges Fierce portfolio with The Conference Forum, Versalinx Global Events
The Fierce network just got stronger. Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers…
Posted inBiotechnology
Mastering the Secrets of Logical Circuit Decoding
In the rapidly evolving realm of computer science, one of the most significant challenges has been deciphering the intricate language…
Posted inBiotechnology
Harmony halts genetic disease program following phase 3 Fragile X failure
After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development…
Posted inBiotechnology
Parexel leaders emphasize AI, workforce evolution in clinical research
Sponsored By Parexel Nov 10, 2025 8:00am At Fierce Biotech Week, Parexel executives Judith Millard and Sheela Hegde highlighted the…
Posted inBiotechnology
Novo, Pfizer’s bidding war heats up with supercharged offers for Metsera
Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes,…
Posted inBiotechnology
PhaseV CEO: Now is the Time to Embrace AI for Clinical Trial Success
Raviv Pryluk, CEO and co-founder of PhaseV, says the pharmaceutical industry must embrace innovation to overcome persistent inefficiencies in clinical…
Posted inBiotechnology
Merck writes tale of 2 checks, bagging $700M from Blackstone and spending $150M to regain asset
Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of…